RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model

, , , ,

On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed infections may have been four times greater than viral tests showed, according to collaborators at the Houston Health Department, Rice University and Baylor College of Medicine.

Tags:


Source: PR Newswire
Credit: